Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Jeffrey Holzbeierlein"'
Autor:
Jian Huang, Wang Liu, Shiqi Song, Jean C. Li, Kaimei Gan, Chunxiao Shen, Jeffrey Holzbeierlein, Benyi Li
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Reliable biomarkers are rare for renal cell carcinoma (RCC) treatment selection. We aimed to discover novel biomarkers for precision medicine. The iron-regulating hormone hepcidin (HAMP) was reportedly increased in RCC patient sera and ti
Externí odkaz:
https://doaj.org/article/c8aa4789f2e045e4a2aca2cf8c3b3ecb
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Alternol and its oxidate isomer Alteronol are small compounds isolated from the fermentation of a mutant fungus obtained from Taxus brevifolia bark. Preclinical studies showed their potent anti-cancer activities, including attenuating cellular surviv
Externí odkaz:
https://doaj.org/article/adf157eee806443b8badcaa6316c6552
Publikováno v:
Case Reports in Urology, Vol 2020 (2020)
We report three cases of prostate adenocarcinoma appearing as bladder masses and misdiagnosed as muscle-invasive bladder cancer (MIBC). Patients were referred for consideration for radical cystectomy after initial pathological diagnosis suggested poo
Externí odkaz:
https://doaj.org/article/6017c17267a94008a78704df01c272ba
Autor:
Andrew J. Armstrong, Taro Iguchi, Arun A. Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Z. Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgiotti, Nader El-Chaar, Arnulf Stenzl
Publikováno v:
European Urology.
Autor:
Arnulf Stenzl, Russell Z. Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D. Shore, Francisco Gomez‐Veiga, Cristina Ivanescu, Brad Rosbrook, Krishnan Ramaswamy, Arijit Ganguli, Gabriel P. Haas, Andrew J. Armstrong
Publikováno v:
The ProstateREFERENCES. 82(13)
Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival versus ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in ARCHES (NCT02677896). While health-related quality of life
Autor:
Taro Iguchi, Arnauld Villers, Neal D. Shore, Arun A. Azad, Russell Z. Szmulewitz, Jeffrey Holzbeierlein, Antonio Alcaraz, Boris Alekseev, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Andrew J. Armstrong, Arnulf Stenzl
Publikováno v:
Journal of Urology. 207
Autor:
Andrew J. Armstrong, Arun A. Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(15)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Autor:
Rahul Atul Parikh, John A. Taylor, Qi Chen, Benjamin L. Woolbright, Ping Chen, Elizabeth Marie Wulff-Burchfield, Jeffrey Holzbeierlein, Roy A. Jensen, Jeanne A. Drisko
Publikováno v:
Journal of Clinical Oncology. 40:e16540-e16540
e16540 Background: Neo-adjuvant cisplatin-based chemotherapy (NAC) is considered standard of care for patients with locally advanced disease. However, ̃40% of patients are cisplatin ineligible (CI) due to renal insufficiency, hearing loss or poor pe
Autor:
Andrew J. Armstrong, Nicolas Mottet, Taro Iguchi, Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Ho-Jin Lee, Gabriel P. Haas, Arnulf Stenzl, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 40:5072-5072
5072 Background: Enzalutamide (ENZA) + androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression and increased overall survival in men with mHSPC, regardless of baseline PSA levels (ARCHES; NCT02677896). This post
Autor:
Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arun Azad, Taro Iguchi, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Brad Rosbrook, Fabian Zohren, Jie Ma, Gabriel P. Haas, Francisco Gomez-Veiga, Arnulf Stenzl, Andrew J. Armstrong
Publikováno v:
Journal of Clinical Oncology. 40:5069-5069
5069 Background: Patients with metastatic prostate cancer aged ≥75 years have a poorer prognosis compared with younger patients. In ARCHES (NCT02677896), ENZA + ADT improved radiographic progression-free survival (rPFS), overall survival (OS), and